Satish Garg
Concepts (662)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypoglycemic Agents | 103 | 2025 | 1301 | 17.590 |
Why?
| | Diabetes Mellitus, Type 1 | 153 | 2025 | 3664 | 17.030 |
Why?
| | Blood Glucose | 117 | 2025 | 2198 | 12.790 |
Why?
| | Blood Glucose Self-Monitoring | 70 | 2025 | 639 | 12.070 |
Why?
| | Insulin | 87 | 2025 | 2405 | 10.760 |
Why?
| | Diabetes Mellitus, Type 2 | 58 | 2025 | 2562 | 8.920 |
Why?
| | Diabetes Mellitus | 32 | 2024 | 1059 | 7.640 |
Why?
| | Hypoglycemia | 50 | 2023 | 445 | 6.660 |
Why?
| | Insulin Infusion Systems | 40 | 2025 | 397 | 6.140 |
Why?
| | Monitoring, Ambulatory | 17 | 2017 | 88 | 4.210 |
Why?
| | Myometrium | 9 | 2021 | 39 | 4.100 |
Why?
| | Buffaloes | 11 | 2021 | 13 | 4.090 |
Why?
| | Diabetic Ketoacidosis | 12 | 2024 | 200 | 3.550 |
Why?
| | Spermatozoa | 8 | 2024 | 96 | 3.480 |
Why?
| | Periodicals as Topic | 7 | 2020 | 212 | 3.130 |
Why?
| | Biosimilar Pharmaceuticals | 6 | 2020 | 24 | 3.070 |
Why?
| | Hyperglycemia | 17 | 2022 | 351 | 2.990 |
Why?
| | Insulin Glargine | 25 | 2022 | 84 | 2.990 |
Why?
| | Glycosides | 10 | 2024 | 37 | 2.900 |
Why?
| | Uterine Contraction | 8 | 2021 | 18 | 2.760 |
Why?
| | Pregnancy in Diabetics | 13 | 2023 | 122 | 2.660 |
Why?
| | Sperm Motility | 7 | 2024 | 32 | 2.550 |
Why?
| | Dog Diseases | 4 | 2021 | 64 | 2.460 |
Why?
| | Insulin Lispro | 14 | 2022 | 39 | 2.420 |
Why?
| | Insulin Aspart | 9 | 2020 | 27 | 2.360 |
Why?
| | Biomedical Technology | 5 | 2023 | 44 | 2.190 |
Why?
| | Mercury | 4 | 2025 | 41 | 2.160 |
Why?
| | Insulin, Long-Acting | 21 | 2022 | 63 | 2.120 |
Why?
| | Overweight | 4 | 2025 | 577 | 2.060 |
Why?
| | Humans | 211 | 2025 | 138102 | 2.060 |
Why?
| | Pancreas, Artificial | 5 | 2024 | 83 | 2.050 |
Why?
| | Cytokines | 7 | 2021 | 2079 | 2.020 |
Why?
| | Calcium | 9 | 2024 | 1183 | 1.930 |
Why?
| | Lead | 3 | 2024 | 64 | 1.750 |
Why?
| | Sperm Capacitation | 6 | 2021 | 12 | 1.620 |
Why?
| | Plant Extracts | 5 | 2019 | 209 | 1.580 |
Why?
| | Telemedicine | 6 | 2021 | 868 | 1.540 |
Why?
| | Antioxidants | 5 | 2020 | 588 | 1.490 |
Why?
| | Female | 118 | 2025 | 73648 | 1.460 |
Why?
| | Adult | 87 | 2025 | 38063 | 1.450 |
Why?
| | Male | 102 | 2025 | 67984 | 1.390 |
Why?
| | Glucagon-Like Peptides | 4 | 2025 | 58 | 1.380 |
Why?
| | Sepsis | 3 | 2023 | 602 | 1.360 |
Why?
| | Theileriasis | 2 | 2020 | 2 | 1.340 |
Why?
| | Insulins | 2 | 2024 | 37 | 1.340 |
Why?
| | Cattle | 9 | 2024 | 987 | 1.310 |
Why?
| | Animals | 52 | 2025 | 37151 | 1.310 |
Why?
| | Mite Infestations | 2 | 2020 | 9 | 1.270 |
Why?
| | Injections, Subcutaneous | 11 | 2021 | 161 | 1.270 |
Why?
| | rho-Associated Kinases | 3 | 2021 | 84 | 1.210 |
Why?
| | Vasoconstriction | 2 | 2022 | 218 | 1.190 |
Why?
| | Calcium Signaling | 3 | 2021 | 249 | 1.190 |
Why?
| | Postprandial Period | 5 | 2020 | 109 | 1.160 |
Why?
| | Pre-Eclampsia | 10 | 2023 | 189 | 1.130 |
Why?
| | Trace Elements | 2 | 2020 | 51 | 1.130 |
Why?
| | Obesity | 4 | 2025 | 3037 | 1.130 |
Why?
| | Middle Aged | 55 | 2025 | 33509 | 1.130 |
Why?
| | Diabetes Complications | 5 | 2020 | 230 | 1.090 |
Why?
| | Drug Therapy, Combination | 14 | 2021 | 1034 | 1.070 |
Why?
| | Trypanosomiasis | 2 | 2017 | 6 | 1.060 |
Why?
| | Non-alcoholic Fatty Liver Disease | 2 | 2021 | 279 | 1.060 |
Why?
| | 3-Hydroxybutyric Acid | 3 | 2024 | 17 | 1.060 |
Why?
| | Insulin, Isophane | 6 | 2017 | 21 | 1.040 |
Why?
| | Dermatitis, Atopic | 2 | 2021 | 329 | 1.020 |
Why?
| | Rats, Wistar | 11 | 2020 | 448 | 1.010 |
Why?
| | Pandemics | 5 | 2022 | 1639 | 1.000 |
Why?
| | Drugs, Investigational | 2 | 2017 | 32 | 0.990 |
Why?
| | Protein Kinase C | 2 | 2018 | 254 | 0.990 |
Why?
| | Histamine | 2 | 2017 | 57 | 0.950 |
Why?
| | Glucagon-Like Peptide 1 | 4 | 2025 | 134 | 0.940 |
Why?
| | Acrosome Reaction | 2 | 2024 | 3 | 0.930 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 370 | 0.910 |
Why?
| | Coronavirus Infections | 2 | 2020 | 368 | 0.900 |
Why?
| | Acrosome | 1 | 2024 | 5 | 0.890 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 3 | 2013 | 46 | 0.880 |
Why?
| | Uterus | 6 | 2021 | 212 | 0.860 |
Why?
| | Monitoring, Physiologic | 6 | 2023 | 270 | 0.840 |
Why?
| | Biomedical Research | 8 | 2017 | 703 | 0.820 |
Why?
| | Treatment Outcome | 22 | 2025 | 10832 | 0.820 |
Why?
| | Diabetic Nephropathies | 2 | 2025 | 301 | 0.810 |
Why?
| | Reproducibility of Results | 14 | 2025 | 3301 | 0.810 |
Why?
| | Weight Loss | 4 | 2025 | 791 | 0.800 |
Why?
| | Angiotensin II | 1 | 2023 | 97 | 0.780 |
Why?
| | Spleen | 3 | 2020 | 521 | 0.770 |
Why?
| | Cross-Over Studies | 10 | 2020 | 550 | 0.770 |
Why?
| | Dinoprost | 2 | 2021 | 44 | 0.760 |
Why?
| | Receptor, Notch3 | 1 | 2022 | 5 | 0.750 |
Why?
| | Sulfones | 2 | 2020 | 110 | 0.750 |
Why?
| | Benzamides | 2 | 2020 | 209 | 0.730 |
Why?
| | Aorta | 2 | 2022 | 417 | 0.730 |
Why?
| | Administration, Inhalation | 4 | 2018 | 588 | 0.720 |
Why?
| | Nifedipine | 6 | 2021 | 28 | 0.710 |
Why?
| | Registries | 8 | 2025 | 2059 | 0.710 |
Why?
| | Intermediate Filament Proteins | 1 | 2021 | 57 | 0.710 |
Why?
| | Glucose | 6 | 2024 | 1033 | 0.700 |
Why?
| | Signal Transduction | 6 | 2024 | 5068 | 0.700 |
Why?
| | Dose-Response Relationship, Drug | 14 | 2020 | 2022 | 0.700 |
Why?
| | Pregnancy | 23 | 2023 | 6789 | 0.700 |
Why?
| | TRPC Cation Channels | 2 | 2021 | 13 | 0.700 |
Why?
| | Type C Phospholipases | 2 | 2018 | 74 | 0.700 |
Why?
| | Insulin Antibodies | 2 | 2020 | 100 | 0.690 |
Why?
| | Arterial Pressure | 1 | 2022 | 132 | 0.690 |
Why?
| | Trypanosoma | 2 | 2017 | 8 | 0.690 |
Why?
| | Dogs | 5 | 2021 | 405 | 0.680 |
Why?
| | Mitochondrial Membranes | 1 | 2021 | 39 | 0.680 |
Why?
| | Biopolymers | 1 | 2020 | 31 | 0.680 |
Why?
| | Endometritis | 2 | 2017 | 4 | 0.680 |
Why?
| | Theileria annulata | 1 | 2020 | 1 | 0.670 |
Why?
| | Chitosan | 1 | 2020 | 34 | 0.670 |
Why?
| | Calcium Channel Blockers | 6 | 2021 | 166 | 0.670 |
Why?
| | Protein Precursors | 1 | 2021 | 133 | 0.670 |
Why?
| | Young Adult | 25 | 2025 | 13329 | 0.670 |
Why?
| | Gelatin | 1 | 2020 | 53 | 0.670 |
Why?
| | Copper Sulfate | 1 | 2020 | 8 | 0.670 |
Why?
| | Betacoronavirus | 2 | 2020 | 270 | 0.660 |
Why?
| | Diabetic Angiopathies | 6 | 2013 | 260 | 0.660 |
Why?
| | Exophthalmos | 1 | 2020 | 19 | 0.660 |
Why?
| | Sodium-Glucose Transporter 1 | 2 | 2017 | 11 | 0.660 |
Why?
| | Mutagens | 1 | 2020 | 23 | 0.660 |
Why?
| | Cattle Diseases | 1 | 2020 | 24 | 0.650 |
Why?
| | Selenium | 1 | 2020 | 47 | 0.650 |
Why?
| | Calcium Channels | 2 | 2018 | 155 | 0.650 |
Why?
| | Sulfonylurea Compounds | 2 | 2018 | 49 | 0.650 |
Why?
| | Patient Education as Topic | 6 | 2020 | 768 | 0.640 |
Why?
| | Peste-des-petits-ruminants virus | 1 | 2019 | 1 | 0.640 |
Why?
| | Polyalthia | 1 | 2019 | 1 | 0.640 |
Why?
| | Oleic Acid | 1 | 2020 | 40 | 0.640 |
Why?
| | Newcastle disease virus | 1 | 2019 | 19 | 0.640 |
Why?
| | Infusions, Subcutaneous | 4 | 2016 | 22 | 0.640 |
Why?
| | Mites | 1 | 2019 | 8 | 0.630 |
Why?
| | Isoproterenol | 1 | 2020 | 101 | 0.630 |
Why?
| | Peroxidase | 2 | 2017 | 178 | 0.630 |
Why?
| | Down-Regulation | 1 | 2022 | 635 | 0.620 |
Why?
| | Potassium Channels | 1 | 2020 | 148 | 0.610 |
Why?
| | Toll-Like Receptors | 1 | 2020 | 188 | 0.600 |
Why?
| | Aged | 25 | 2024 | 23995 | 0.600 |
Why?
| | Oxidative Stress | 4 | 2020 | 1322 | 0.590 |
Why?
| | Uterine Artery | 1 | 2019 | 74 | 0.590 |
Why?
| | Cardiovascular Diseases | 3 | 2025 | 2121 | 0.590 |
Why?
| | Mercuric Chloride | 1 | 2018 | 2 | 0.580 |
Why?
| | Endocannabinoids | 2 | 2019 | 64 | 0.580 |
Why?
| | GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2018 | 20 | 0.580 |
Why?
| | Biosensing Techniques | 2 | 2018 | 134 | 0.570 |
Why?
| | Voltage-Gated Sodium Channels | 1 | 2017 | 5 | 0.560 |
Why?
| | Tocolysis | 1 | 2017 | 4 | 0.560 |
Why?
| | Ethanolamines | 1 | 2017 | 14 | 0.560 |
Why?
| | Weight Gain | 6 | 2024 | 538 | 0.560 |
Why?
| | Eucalyptus | 1 | 2017 | 8 | 0.560 |
Why?
| | Wound Healing | 1 | 2020 | 343 | 0.560 |
Why?
| | KATP Channels | 1 | 2017 | 20 | 0.560 |
Why?
| | Potassium Channels, Voltage-Gated | 1 | 2018 | 50 | 0.560 |
Why?
| | Vasodilation | 2 | 2019 | 514 | 0.550 |
Why?
| | Double-Blind Method | 9 | 2024 | 1922 | 0.550 |
Why?
| | Oxytocin | 2 | 2016 | 51 | 0.550 |
Why?
| | Norepinephrine | 1 | 2018 | 191 | 0.550 |
Why?
| | Adolescent | 30 | 2022 | 21637 | 0.550 |
Why?
| | Interleukins | 1 | 2019 | 251 | 0.540 |
Why?
| | Immunoglobulin E | 1 | 2019 | 325 | 0.540 |
Why?
| | Endothelium, Vascular | 3 | 2019 | 934 | 0.540 |
Why?
| | Hydrogen Sulfide | 1 | 2017 | 44 | 0.540 |
Why?
| | Self Care | 4 | 2013 | 386 | 0.530 |
Why?
| | NAV1.8 Voltage-Gated Sodium Channel | 1 | 2016 | 3 | 0.530 |
Why?
| | Syringes | 3 | 2013 | 43 | 0.530 |
Why?
| | Coinfection | 1 | 2018 | 138 | 0.520 |
Why?
| | Cadmium | 1 | 2017 | 69 | 0.520 |
Why?
| | Therapies, Investigational | 1 | 2017 | 18 | 0.520 |
Why?
| | Reactive Oxygen Species | 1 | 2020 | 626 | 0.520 |
Why?
| | Hospitalization | 2 | 2024 | 2195 | 0.520 |
Why?
| | Inflammation Mediators | 1 | 2020 | 511 | 0.520 |
Why?
| | Mitochondria | 2 | 2021 | 951 | 0.510 |
Why?
| | Muscle Relaxation | 1 | 2016 | 29 | 0.510 |
Why?
| | Cholinesterases | 1 | 2016 | 9 | 0.510 |
Why?
| | Minerals | 1 | 2016 | 42 | 0.510 |
Why?
| | Diffusion of Innovation | 1 | 2017 | 98 | 0.500 |
Why?
| | Receptors, Adrenergic, beta | 1 | 2016 | 66 | 0.490 |
Why?
| | Calcium Channels, L-Type | 1 | 2017 | 117 | 0.490 |
Why?
| | Ambulatory Care Facilities | 2 | 2023 | 244 | 0.480 |
Why?
| | Insulin, Regular, Human | 3 | 2024 | 43 | 0.470 |
Why?
| | Body Mass Index | 8 | 2025 | 2422 | 0.470 |
Why?
| | Myocytes, Cardiac | 1 | 2020 | 505 | 0.470 |
Why?
| | Disposable Equipment | 2 | 2013 | 19 | 0.470 |
Why?
| | Vitamins | 1 | 2016 | 188 | 0.460 |
Why?
| | Consensus | 7 | 2023 | 676 | 0.460 |
Why?
| | United States | 17 | 2025 | 15028 | 0.460 |
Why?
| | Insulin Detemir | 5 | 2017 | 8 | 0.460 |
Why?
| | Gene Expression | 1 | 2020 | 1487 | 0.450 |
Why?
| | Drug Delivery Systems | 2 | 2018 | 357 | 0.450 |
Why?
| | Biomarkers | 12 | 2025 | 4111 | 0.440 |
Why?
| | Prospective Studies | 14 | 2025 | 7603 | 0.440 |
Why?
| | Rats | 7 | 2020 | 5564 | 0.440 |
Why?
| | Drug Administration Schedule | 8 | 2017 | 753 | 0.430 |
Why?
| | Withania | 1 | 2013 | 6 | 0.420 |
Why?
| | Glucagon | 2 | 2022 | 105 | 0.420 |
Why?
| | Receptors, Adrenergic, alpha-1 | 1 | 2013 | 45 | 0.410 |
Why?
| | Antiviral Agents | 1 | 2019 | 759 | 0.410 |
Why?
| | Extracellular Fluid | 1 | 2013 | 31 | 0.410 |
Why?
| | Glucosides | 3 | 2019 | 47 | 0.400 |
Why?
| | Nervous System Diseases | 1 | 2016 | 273 | 0.400 |
Why?
| | Chlorpyrifos | 1 | 2013 | 7 | 0.400 |
Why?
| | Benzhydryl Compounds | 3 | 2019 | 76 | 0.390 |
Why?
| | Retrospective Studies | 10 | 2025 | 15750 | 0.390 |
Why?
| | Membrane Potential, Mitochondrial | 3 | 2024 | 73 | 0.390 |
Why?
| | History, 21st Century | 3 | 2020 | 213 | 0.390 |
Why?
| | Microsomes, Liver | 1 | 2013 | 81 | 0.390 |
Why?
| | Myocardial Infarction | 1 | 2020 | 1053 | 0.380 |
Why?
| | Portal Vein | 1 | 2013 | 118 | 0.380 |
Why?
| | Time Factors | 12 | 2021 | 6845 | 0.380 |
Why?
| | Arsenic | 1 | 2013 | 63 | 0.370 |
Why?
| | Pyrazines | 1 | 2013 | 85 | 0.370 |
Why?
| | Pregnancy Outcome | 3 | 2023 | 421 | 0.370 |
Why?
| | Tocolytic Agents | 2 | 2017 | 16 | 0.360 |
Why?
| | Triazoles | 1 | 2013 | 152 | 0.360 |
Why?
| | Patient Preference | 1 | 2013 | 197 | 0.360 |
Why?
| | Ascorbic Acid | 1 | 2013 | 178 | 0.350 |
Why?
| | Needles | 1 | 2011 | 61 | 0.350 |
Why?
| | Prevalence | 8 | 2020 | 2762 | 0.350 |
Why?
| | Goats | 2 | 2021 | 27 | 0.350 |
Why?
| | Adrenergic beta-Agonists | 2 | 2017 | 98 | 0.350 |
Why?
| | Clinical Trials as Topic | 7 | 2022 | 1032 | 0.340 |
Why?
| | History, 20th Century | 3 | 2019 | 325 | 0.330 |
Why?
| | Blood Chemical Analysis | 2 | 2017 | 109 | 0.320 |
Why?
| | Acetylcholine | 3 | 2019 | 204 | 0.320 |
Why?
| | Nitric Oxide Synthase Type II | 2 | 2022 | 173 | 0.310 |
Why?
| | Water Pollutants, Chemical | 1 | 2013 | 217 | 0.310 |
Why?
| | DNA Damage | 2 | 2024 | 422 | 0.310 |
Why?
| | Calibration | 3 | 2018 | 146 | 0.310 |
Why?
| | China | 4 | 2020 | 214 | 0.310 |
Why?
| | Organometallic Compounds | 2 | 2024 | 110 | 0.310 |
Why?
| | Pregnancy Trimester, First | 3 | 2020 | 137 | 0.310 |
Why?
| | 4-Aminopyridine | 2 | 2020 | 24 | 0.310 |
Why?
| | Intention to Treat Analysis | 3 | 2017 | 74 | 0.300 |
Why?
| | Health Care Costs | 4 | 2016 | 398 | 0.300 |
Why?
| | Reference Values | 6 | 2023 | 803 | 0.300 |
Why?
| | Plant Leaves | 3 | 2019 | 149 | 0.290 |
Why?
| | alpha-Tocopherol | 2 | 2020 | 32 | 0.290 |
Why?
| | Research Design | 6 | 2015 | 1122 | 0.290 |
Why?
| | Prediabetic State | 1 | 2011 | 249 | 0.290 |
Why?
| | Computer Systems | 2 | 2018 | 45 | 0.290 |
Why?
| | Animals, Newborn | 2 | 2020 | 847 | 0.280 |
Why?
| | Veratridine | 2 | 2017 | 5 | 0.270 |
Why?
| | Blood Pressure | 4 | 2025 | 1802 | 0.270 |
Why?
| | Anti-Bacterial Agents | 1 | 2017 | 1804 | 0.270 |
Why?
| | Software | 3 | 2013 | 665 | 0.270 |
Why?
| | Equipment Design | 4 | 2010 | 510 | 0.260 |
Why?
| | Sodium-Glucose Transport Proteins | 2 | 2017 | 2 | 0.260 |
Why?
| | Nitric Oxide | 3 | 2022 | 895 | 0.250 |
Why?
| | Child | 11 | 2022 | 21990 | 0.250 |
Why?
| | United States Food and Drug Administration | 3 | 2018 | 200 | 0.250 |
Why?
| | Vasodilator Agents | 2 | 2019 | 326 | 0.250 |
Why?
| | Journal Impact Factor | 2 | 2020 | 28 | 0.250 |
Why?
| | Risk Factors | 8 | 2024 | 10433 | 0.240 |
Why?
| | Ruthenium Red | 2 | 2016 | 7 | 0.240 |
Why?
| | Blotting, Western | 3 | 2017 | 1223 | 0.240 |
Why?
| | Diabetic Retinopathy | 2 | 2005 | 190 | 0.240 |
Why?
| | Albuminuria | 3 | 2017 | 187 | 0.240 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2021 | 1239 | 0.240 |
Why?
| | Hypertension | 4 | 2011 | 1310 | 0.230 |
Why?
| | Tissue Culture Techniques | 2 | 2017 | 82 | 0.230 |
Why?
| | Copper | 2 | 2016 | 110 | 0.230 |
Why?
| | Lipoproteins | 2 | 2019 | 166 | 0.230 |
Why?
| | Phenylephrine | 2 | 2016 | 74 | 0.230 |
Why?
| | Large-Conductance Calcium-Activated Potassium Channels | 2 | 2017 | 11 | 0.230 |
Why?
| | Algorithms | 5 | 2018 | 1711 | 0.230 |
Why?
| | Glomerular Filtration Rate | 3 | 2025 | 746 | 0.230 |
Why?
| | Exercise | 2 | 2014 | 2077 | 0.230 |
Why?
| | Fasting | 1 | 2006 | 284 | 0.230 |
Why?
| | Body Weight | 7 | 2020 | 990 | 0.220 |
Why?
| | Semen Analysis | 1 | 2024 | 14 | 0.220 |
Why?
| | Calcinosis | 4 | 2010 | 235 | 0.220 |
Why?
| | Adrenergic beta-2 Receptor Agonists | 1 | 2004 | 27 | 0.220 |
Why?
| | Glucagon-Like Peptide-2 Receptor | 1 | 2024 | 9 | 0.220 |
Why?
| | Gastric Inhibitory Polypeptide | 1 | 2024 | 14 | 0.220 |
Why?
| | Phosphorylation | 2 | 2020 | 1760 | 0.220 |
Why?
| | Pyrazoles | 2 | 2018 | 421 | 0.210 |
Why?
| | Cyclic AMP | 1 | 2024 | 219 | 0.210 |
Why?
| | Drug Approval | 1 | 2024 | 87 | 0.210 |
Why?
| | Uridine Diphosphate | 1 | 2023 | 3 | 0.210 |
Why?
| | Equipment Failure | 2 | 2018 | 105 | 0.200 |
Why?
| | Reproduction | 1 | 2025 | 205 | 0.200 |
Why?
| | Mass Screening | 1 | 2011 | 1303 | 0.200 |
Why?
| | Dietary Supplements | 2 | 2018 | 565 | 0.200 |
Why?
| | Endocrinology | 2 | 2016 | 76 | 0.190 |
Why?
| | Receptors, Glucagon | 1 | 2022 | 26 | 0.190 |
Why?
| | Vitamin D-Binding Protein | 2 | 2020 | 15 | 0.190 |
Why?
| | Aged, 80 and over | 3 | 2022 | 7638 | 0.190 |
Why?
| | Safety | 3 | 2009 | 345 | 0.190 |
Why?
| | Randomized Controlled Trials as Topic | 5 | 2021 | 1473 | 0.180 |
Why?
| | Ketosis | 1 | 2021 | 12 | 0.180 |
Why?
| | Mice | 5 | 2023 | 17769 | 0.180 |
Why?
| | Reference Standards | 4 | 2017 | 184 | 0.180 |
Why?
| | Mobile Applications | 2 | 2021 | 178 | 0.180 |
Why?
| | Testis | 2 | 2025 | 156 | 0.180 |
Why?
| | Illinois | 1 | 2021 | 45 | 0.170 |
Why?
| | Immunization, Passive | 1 | 2021 | 91 | 0.170 |
Why?
| | Patient Isolation | 1 | 2021 | 19 | 0.170 |
Why?
| | New York City | 1 | 2021 | 86 | 0.170 |
Why?
| | Los Angeles | 1 | 2021 | 77 | 0.170 |
Why?
| | Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2020 | 50 | 0.170 |
Why?
| | Child, Preschool | 5 | 2022 | 11142 | 0.170 |
Why?
| | Micronucleus Tests | 1 | 2020 | 7 | 0.170 |
Why?
| | Comet Assay | 1 | 2020 | 16 | 0.170 |
Why?
| | Antigens, Viral | 1 | 2021 | 179 | 0.170 |
Why?
| | Patient Satisfaction | 3 | 2015 | 681 | 0.170 |
Why?
| | Skin Diseases, Parasitic | 1 | 2020 | 3 | 0.160 |
Why?
| | Interleukin-13 | 1 | 2021 | 148 | 0.160 |
Why?
| | Progesterone | 2 | 2019 | 256 | 0.160 |
Why?
| | Uncoupling Protein 2 | 1 | 2020 | 8 | 0.160 |
Why?
| | Chromium | 1 | 2020 | 15 | 0.160 |
Why?
| | Environmental Exposure | 1 | 2025 | 574 | 0.160 |
Why?
| | Cardiotoxicity | 1 | 2020 | 27 | 0.160 |
Why?
| | Practice Guidelines as Topic | 3 | 2019 | 1557 | 0.160 |
Why?
| | Incidence | 3 | 2017 | 2827 | 0.160 |
Why?
| | Intermediate-Conductance Calcium-Activated Potassium Channels | 1 | 2019 | 1 | 0.160 |
Why?
| | Curcumin | 1 | 2020 | 29 | 0.160 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2020 | 165 | 0.160 |
Why?
| | Disease Models, Animal | 2 | 2020 | 4309 | 0.160 |
Why?
| | Glycemic Index | 2 | 2009 | 28 | 0.160 |
Why?
| | Income | 1 | 2021 | 204 | 0.160 |
Why?
| | Cyclooxygenase 1 | 1 | 2019 | 28 | 0.160 |
Why?
| | Small-Conductance Calcium-Activated Potassium Channels | 1 | 2019 | 12 | 0.160 |
Why?
| | Vero Cells | 1 | 2019 | 85 | 0.160 |
Why?
| | Lipid Peroxidation | 1 | 2020 | 152 | 0.160 |
Why?
| | Virus Internalization | 1 | 2019 | 66 | 0.160 |
Why?
| | Haptoglobins | 1 | 2019 | 54 | 0.150 |
Why?
| | Canagliflozin | 1 | 2019 | 10 | 0.150 |
Why?
| | Area Under Curve | 3 | 2015 | 306 | 0.150 |
Why?
| | Tyrosine | 1 | 2020 | 226 | 0.150 |
Why?
| | Host-Parasite Interactions | 1 | 2020 | 118 | 0.150 |
Why?
| | Adamantane | 1 | 2019 | 17 | 0.150 |
Why?
| | Diabetes, Gestational | 1 | 2023 | 322 | 0.150 |
Why?
| | Immunity, Cellular | 2 | 2018 | 270 | 0.150 |
Why?
| | Dipeptides | 1 | 2019 | 50 | 0.150 |
Why?
| | Ion Channels | 1 | 2019 | 128 | 0.150 |
Why?
| | Liver Cirrhosis | 1 | 2021 | 312 | 0.150 |
Why?
| | TRPV Cation Channels | 1 | 2019 | 41 | 0.150 |
Why?
| | California | 1 | 2020 | 439 | 0.150 |
Why?
| | Vitamin D | 2 | 2020 | 398 | 0.150 |
Why?
| | Congresses as Topic | 2 | 2020 | 228 | 0.150 |
Why?
| | Methyldopa | 1 | 2018 | 7 | 0.140 |
Why?
| | Meals | 1 | 2020 | 129 | 0.140 |
Why?
| | Patient Care Planning | 1 | 2019 | 151 | 0.140 |
Why?
| | Receptor, Cannabinoid, CB1 | 1 | 2018 | 46 | 0.140 |
Why?
| | Self Efficacy | 1 | 2002 | 402 | 0.140 |
Why?
| | Organ Culture Techniques | 1 | 2018 | 156 | 0.140 |
Why?
| | Aminooxyacetic Acid | 1 | 2017 | 1 | 0.140 |
Why?
| | Sodium Channel Agonists | 1 | 2017 | 1 | 0.140 |
Why?
| | Receptors, Adrenergic, beta-3 | 1 | 2017 | 4 | 0.140 |
Why?
| | Sensitivity and Specificity | 4 | 2009 | 1946 | 0.140 |
Why?
| | International Agencies | 1 | 2017 | 34 | 0.140 |
Why?
| | Injections | 1 | 2018 | 187 | 0.140 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2020 | 552 | 0.140 |
Why?
| | Hemoglobin A | 1 | 2017 | 21 | 0.140 |
Why?
| | Administration, Oral | 2 | 2017 | 786 | 0.140 |
Why?
| | Malondialdehyde | 1 | 2017 | 29 | 0.140 |
Why?
| | Sodium Bicarbonate | 1 | 2018 | 46 | 0.140 |
Why?
| | Serum Amyloid A Protein | 1 | 2017 | 33 | 0.140 |
Why?
| | Equivalence Trials as Topic | 1 | 2017 | 9 | 0.140 |
Why?
| | Analysis of Variance | 1 | 2020 | 1311 | 0.140 |
Why?
| | Glyburide | 1 | 2017 | 32 | 0.140 |
Why?
| | Propanolamines | 1 | 2017 | 32 | 0.140 |
Why?
| | Toll-Like Receptor 9 | 1 | 2017 | 33 | 0.140 |
Why?
| | Methanol | 1 | 2017 | 42 | 0.140 |
Why?
| | Alkynes | 1 | 2017 | 57 | 0.140 |
Why?
| | Least-Squares Analysis | 1 | 2017 | 79 | 0.140 |
Why?
| | Protein Carbonylation | 1 | 2017 | 55 | 0.140 |
Why?
| | Biomechanical Phenomena | 1 | 2021 | 815 | 0.140 |
Why?
| | HLA-DQ Antigens | 1 | 2018 | 177 | 0.130 |
Why?
| | Adipokines | 1 | 2017 | 47 | 0.130 |
Why?
| | Solvents | 1 | 2017 | 110 | 0.130 |
Why?
| | Data Interpretation, Statistical | 1 | 2019 | 360 | 0.130 |
Why?
| | Patient Dropouts | 1 | 2017 | 62 | 0.130 |
Why?
| | Immunization | 1 | 2019 | 405 | 0.130 |
Why?
| | Islet Amyloid Polypeptide | 3 | 2013 | 47 | 0.130 |
Why?
| | Phytotherapy | 1 | 2017 | 86 | 0.130 |
Why?
| | Patient Compliance | 2 | 2013 | 595 | 0.130 |
Why?
| | Antibodies, Viral | 1 | 2021 | 648 | 0.130 |
Why?
| | Cyclooxygenase 2 | 1 | 2017 | 176 | 0.130 |
Why?
| | Anniversaries and Special Events | 1 | 2017 | 18 | 0.130 |
Why?
| | Longitudinal Studies | 6 | 2020 | 2861 | 0.130 |
Why?
| | Fatty Acids, Nonesterified | 1 | 2017 | 158 | 0.130 |
Why?
| | Computer-Aided Design | 1 | 2017 | 41 | 0.130 |
Why?
| | Furans | 1 | 2016 | 24 | 0.130 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2022 | 815 | 0.130 |
Why?
| | Clinical Protocols | 1 | 2018 | 267 | 0.130 |
Why?
| | Uric Acid | 1 | 2018 | 165 | 0.130 |
Why?
| | Up-Regulation | 1 | 2020 | 844 | 0.130 |
Why?
| | Antigen Presentation | 1 | 2018 | 220 | 0.130 |
Why?
| | Glycine | 1 | 2017 | 175 | 0.130 |
Why?
| | Indicators and Reagents | 1 | 2016 | 109 | 0.130 |
Why?
| | Sympathomimetics | 1 | 2016 | 19 | 0.130 |
Why?
| | Coronary Artery Disease | 3 | 2010 | 701 | 0.130 |
Why?
| | Oleaceae | 1 | 2016 | 1 | 0.130 |
Why?
| | Cell Survival | 1 | 2020 | 1130 | 0.130 |
Why?
| | In Vitro Techniques | 2 | 2016 | 1088 | 0.130 |
Why?
| | Combined Modality Therapy | 2 | 2017 | 1234 | 0.130 |
Why?
| | Antibody Formation | 1 | 2018 | 298 | 0.130 |
Why?
| | Piperidines | 1 | 2018 | 208 | 0.130 |
Why?
| | Antihypertensive Agents | 3 | 2012 | 499 | 0.130 |
Why?
| | Cysteine | 1 | 2017 | 203 | 0.130 |
Why?
| | Lung | 1 | 2009 | 4065 | 0.120 |
Why?
| | Socioeconomic Factors | 1 | 2021 | 1312 | 0.120 |
Why?
| | Anti-Inflammatory Agents | 1 | 2020 | 470 | 0.120 |
Why?
| | Eating | 3 | 2009 | 397 | 0.120 |
Why?
| | Aniline Compounds | 1 | 2016 | 102 | 0.120 |
Why?
| | Comorbidity | 1 | 2021 | 1638 | 0.120 |
Why?
| | Drug Hypersensitivity | 1 | 2017 | 93 | 0.120 |
Why?
| | Amyloid | 2 | 2007 | 91 | 0.120 |
Why?
| | Pilot Projects | 2 | 2018 | 1751 | 0.120 |
Why?
| | Leptin | 2 | 2017 | 242 | 0.120 |
Why?
| | Membrane Potentials | 1 | 2016 | 281 | 0.120 |
Why?
| | Forecasting | 2 | 2016 | 388 | 0.120 |
Why?
| | Drug Design | 1 | 2017 | 165 | 0.120 |
Why?
| | Moringa oleifera | 1 | 2015 | 3 | 0.120 |
Why?
| | Estradiol | 1 | 2019 | 525 | 0.120 |
Why?
| | Incretins | 1 | 2015 | 22 | 0.120 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2016 | 276 | 0.120 |
Why?
| | Interleukin-10 | 1 | 2017 | 302 | 0.120 |
Why?
| | Vascular Stiffness | 1 | 2021 | 497 | 0.120 |
Why?
| | Postnatal Care | 1 | 2016 | 71 | 0.120 |
Why?
| | Imidazoles | 1 | 2016 | 236 | 0.120 |
Why?
| | Toll-Like Receptor 4 | 1 | 2017 | 272 | 0.120 |
Why?
| | RNA, Messenger | 1 | 2023 | 2799 | 0.120 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 2 | 2013 | 255 | 0.110 |
Why?
| | Cells, Cultured | 2 | 2020 | 4160 | 0.110 |
Why?
| | Early Diagnosis | 2 | 2015 | 238 | 0.110 |
Why?
| | Disease Management | 1 | 2019 | 620 | 0.110 |
Why?
| | Materials Testing | 2 | 2017 | 349 | 0.110 |
Why?
| | Cholesterol, HDL | 1 | 2015 | 204 | 0.110 |
Why?
| | Estrenes | 1 | 2014 | 16 | 0.110 |
Why?
| | Vitamin D Deficiency | 2 | 2020 | 186 | 0.110 |
Why?
| | Self-Management | 1 | 2017 | 181 | 0.110 |
Why?
| | Pyrrolidinones | 1 | 2014 | 30 | 0.110 |
Why?
| | Case-Control Studies | 2 | 2019 | 3569 | 0.110 |
Why?
| | Gastrins | 1 | 2013 | 8 | 0.110 |
Why?
| | Colesevelam Hydrochloride | 1 | 2013 | 8 | 0.110 |
Why?
| | Allylamine | 1 | 2013 | 8 | 0.110 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2014 | 76 | 0.110 |
Why?
| | Bromocriptine | 1 | 2013 | 31 | 0.110 |
Why?
| | Sodium-Glucose Transporter 2 | 1 | 2013 | 26 | 0.100 |
Why?
| | Inflammation | 1 | 2005 | 2847 | 0.100 |
Why?
| | Colorado | 2 | 2020 | 4553 | 0.100 |
Why?
| | Staphylococcus aureus | 1 | 2017 | 432 | 0.100 |
Why?
| | Kidney Diseases | 1 | 2017 | 409 | 0.100 |
Why?
| | Catecholamines | 1 | 2013 | 89 | 0.100 |
Why?
| | Staining and Labeling | 1 | 2014 | 155 | 0.100 |
Why?
| | Prenatal Care | 1 | 2016 | 300 | 0.100 |
Why?
| | Immunohistochemistry | 1 | 2017 | 1718 | 0.100 |
Why?
| | Immunologic Factors | 1 | 2015 | 239 | 0.100 |
Why?
| | Escherichia coli | 1 | 2017 | 826 | 0.100 |
Why?
| | Chemistry, Pharmaceutical | 1 | 2013 | 104 | 0.100 |
Why?
| | Toxicity Tests, Subacute | 1 | 2013 | 1 | 0.100 |
Why?
| | Coronary Disease | 2 | 2007 | 373 | 0.100 |
Why?
| | Enzyme Inhibitors | 1 | 2016 | 847 | 0.100 |
Why?
| | Autoantibodies | 2 | 2018 | 1454 | 0.100 |
Why?
| | Age Factors | 2 | 2019 | 3285 | 0.100 |
Why?
| | Sitagliptin Phosphate | 1 | 2013 | 32 | 0.100 |
Why?
| | Cooperative Behavior | 1 | 2016 | 458 | 0.100 |
Why?
| | Menopause | 1 | 2016 | 326 | 0.100 |
Why?
| | Thiazolidinediones | 1 | 2013 | 139 | 0.100 |
Why?
| | Oxidation-Reduction | 1 | 2016 | 1075 | 0.100 |
Why?
| | Quality of Life | 5 | 2016 | 2936 | 0.100 |
Why?
| | Delayed-Action Preparations | 1 | 2013 | 173 | 0.100 |
Why?
| | Patient Selection | 2 | 2009 | 692 | 0.100 |
Why?
| | Leadership | 1 | 2017 | 394 | 0.100 |
Why?
| | Insecticides | 1 | 2013 | 42 | 0.100 |
Why?
| | Islets of Langerhans Transplantation | 1 | 2013 | 64 | 0.100 |
Why?
| | T-Lymphocytes | 2 | 2018 | 1983 | 0.090 |
Why?
| | Gene Expression Regulation | 2 | 2019 | 2586 | 0.090 |
Why?
| | Circadian Rhythm | 4 | 2015 | 478 | 0.090 |
Why?
| | Zinc | 1 | 2015 | 301 | 0.090 |
Why?
| | Cell Proliferation | 2 | 2016 | 2472 | 0.090 |
Why?
| | Drinking Water | 1 | 2013 | 84 | 0.090 |
Why?
| | Self Administration | 1 | 2011 | 124 | 0.090 |
Why?
| | Internet | 1 | 2016 | 681 | 0.090 |
Why?
| | Carotenoids | 1 | 2011 | 43 | 0.090 |
Why?
| | Managed Care Programs | 1 | 2011 | 141 | 0.090 |
Why?
| | Swine | 1 | 2013 | 796 | 0.090 |
Why?
| | Cohort Studies | 4 | 2019 | 5731 | 0.080 |
Why?
| | Regression Analysis | 2 | 2010 | 1012 | 0.080 |
Why?
| | Eicosapentaenoic Acid | 1 | 2010 | 38 | 0.080 |
Why?
| | Home Care Services | 1 | 2013 | 259 | 0.080 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 351 | 0.080 |
Why?
| | Metformin | 1 | 2013 | 337 | 0.080 |
Why?
| | Surveys and Questionnaires | 4 | 2014 | 5850 | 0.080 |
Why?
| | Drug Combinations | 1 | 2010 | 341 | 0.080 |
Why?
| | Carcinogens | 1 | 2009 | 126 | 0.070 |
Why?
| | Decision Making | 2 | 2013 | 941 | 0.070 |
Why?
| | Physicians | 2 | 2017 | 929 | 0.070 |
Why?
| | Vital Capacity | 1 | 2009 | 302 | 0.070 |
Why?
| | Disease Progression | 3 | 2012 | 2730 | 0.070 |
Why?
| | Forced Expiratory Volume | 1 | 2009 | 481 | 0.070 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 2 | 2018 | 42 | 0.070 |
Why?
| | Rats, Sprague-Dawley | 1 | 2013 | 2472 | 0.070 |
Why?
| | Cross-Sectional Studies | 4 | 2015 | 5556 | 0.070 |
Why?
| | Immunosuppressive Agents | 1 | 2013 | 863 | 0.070 |
Why?
| | Angiotensin II Type 2 Receptor Blockers | 1 | 2007 | 7 | 0.070 |
Why?
| | Norway | 2 | 2019 | 43 | 0.070 |
Why?
| | C-Reactive Protein | 2 | 2013 | 415 | 0.070 |
Why?
| | Drug Costs | 1 | 2008 | 106 | 0.070 |
Why?
| | Medication Adherence | 1 | 2011 | 497 | 0.070 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2007 | 71 | 0.070 |
Why?
| | Sheep | 1 | 2010 | 853 | 0.070 |
Why?
| | Nebulizers and Vaporizers | 1 | 2007 | 66 | 0.070 |
Why?
| | Infusion Pumps, Implantable | 2 | 2004 | 24 | 0.070 |
Why?
| | Renin-Angiotensin System | 1 | 2007 | 78 | 0.060 |
Why?
| | Risk Management | 2 | 2019 | 92 | 0.060 |
Why?
| | Australia | 2 | 2019 | 316 | 0.060 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2007 | 195 | 0.060 |
Why?
| | Societies, Medical | 1 | 2010 | 820 | 0.060 |
Why?
| | Infant | 1 | 2020 | 9566 | 0.060 |
Why?
| | Creatinine | 2 | 2018 | 487 | 0.060 |
Why?
| | Patient Acceptance of Health Care | 1 | 2012 | 845 | 0.060 |
Why?
| | Alprostadil | 1 | 2005 | 32 | 0.060 |
Why?
| | Attitude of Health Personnel | 1 | 2013 | 1157 | 0.060 |
Why?
| | Immunity, Humoral | 2 | 2016 | 117 | 0.060 |
Why?
| | Barium Compounds | 1 | 2004 | 12 | 0.060 |
Why?
| | Terbutaline | 1 | 2004 | 8 | 0.060 |
Why?
| | Organ Size | 2 | 2016 | 473 | 0.060 |
Why?
| | Spermatogenesis | 1 | 2025 | 69 | 0.060 |
Why?
| | Potassium Chloride | 1 | 2004 | 43 | 0.060 |
Why?
| | Abortifacient Agents, Nonsteroidal | 1 | 2004 | 20 | 0.060 |
Why?
| | Receptors, Adrenergic, beta-2 | 1 | 2004 | 33 | 0.060 |
Why?
| | Dinoprostone | 1 | 2005 | 192 | 0.050 |
Why?
| | Hyperlipidemias | 1 | 2005 | 124 | 0.050 |
Why?
| | Albuterol | 1 | 2004 | 74 | 0.050 |
Why?
| | Automation | 1 | 2004 | 95 | 0.050 |
Why?
| | Pulmonary Artery | 1 | 2010 | 1108 | 0.050 |
Why?
| | Capillaries | 1 | 2004 | 108 | 0.050 |
Why?
| | Chlorides | 1 | 2004 | 139 | 0.050 |
Why?
| | Homeostasis | 1 | 2007 | 618 | 0.050 |
Why?
| | Modems | 1 | 2003 | 1 | 0.050 |
Why?
| | Fetal Macrosomia | 1 | 2003 | 62 | 0.050 |
Why?
| | Glycation End Products, Advanced | 1 | 2023 | 83 | 0.050 |
Why?
| | Transaminases | 1 | 2022 | 23 | 0.050 |
Why?
| | Food | 1 | 2004 | 168 | 0.050 |
Why?
| | Congenital Abnormalities | 1 | 2003 | 93 | 0.050 |
Why?
| | Primary Health Care | 1 | 2013 | 1782 | 0.050 |
Why?
| | Costs and Cost Analysis | 1 | 2003 | 211 | 0.050 |
Why?
| | Lipoproteins, LDL | 1 | 2022 | 115 | 0.050 |
Why?
| | Educational Status | 1 | 2004 | 474 | 0.050 |
Why?
| | Ketone Bodies | 1 | 2021 | 14 | 0.050 |
Why?
| | Follow-Up Studies | 2 | 2020 | 5144 | 0.040 |
Why?
| | Brain | 1 | 2013 | 2725 | 0.040 |
Why?
| | Preconception Care | 1 | 2002 | 43 | 0.040 |
Why?
| | Age of Onset | 1 | 2003 | 522 | 0.040 |
Why?
| | Labor, Obstetric | 1 | 2002 | 62 | 0.040 |
Why?
| | Breath Tests | 1 | 2021 | 75 | 0.040 |
Why?
| | Prognosis | 2 | 2020 | 3982 | 0.040 |
Why?
| | Ketones | 1 | 2021 | 47 | 0.040 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2021 | 97 | 0.040 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2005 | 451 | 0.040 |
Why?
| | Pregnancy Trimester, Second | 1 | 2020 | 80 | 0.040 |
Why?
| | Learning | 1 | 2004 | 416 | 0.040 |
Why?
| | Self Concept | 1 | 2002 | 256 | 0.040 |
Why?
| | Birth Weight | 1 | 2003 | 511 | 0.040 |
Why?
| | Immunoglobulin Fc Fragments | 1 | 2020 | 43 | 0.040 |
Why?
| | Gestational Age | 1 | 2003 | 915 | 0.040 |
Why?
| | Skin | 1 | 2004 | 753 | 0.040 |
Why?
| | Vascular Resistance | 1 | 2021 | 374 | 0.040 |
Why?
| | Polyunsaturated Alkamides | 1 | 2019 | 10 | 0.040 |
Why?
| | Capsaicin | 1 | 2019 | 29 | 0.040 |
Why?
| | Data Accuracy | 1 | 2019 | 65 | 0.040 |
Why?
| | Postpartum Period | 1 | 2002 | 343 | 0.040 |
Why?
| | Immunoblotting | 1 | 2019 | 306 | 0.040 |
Why?
| | Arachidonic Acids | 1 | 2019 | 64 | 0.040 |
Why?
| | Databases, Factual | 1 | 2004 | 1381 | 0.040 |
Why?
| | Internationality | 1 | 2019 | 159 | 0.040 |
Why?
| | Microscopy, Polarization | 1 | 2018 | 31 | 0.040 |
Why?
| | Osmolar Concentration | 1 | 2018 | 168 | 0.030 |
Why?
| | Sodium | 1 | 2019 | 200 | 0.030 |
Why?
| | Retinol-Binding Proteins, Plasma | 1 | 2017 | 6 | 0.030 |
Why?
| | Resistin | 1 | 2017 | 11 | 0.030 |
Why?
| | Multicenter Studies as Topic | 1 | 2019 | 307 | 0.030 |
Why?
| | Sleep | 2 | 2015 | 793 | 0.030 |
Why?
| | Lipocalin-2 | 1 | 2017 | 79 | 0.030 |
Why?
| | North America | 1 | 2018 | 309 | 0.030 |
Why?
| | Survival Rate | 1 | 2022 | 1912 | 0.030 |
Why?
| | Lost to Follow-Up | 1 | 2017 | 18 | 0.030 |
Why?
| | Fatty Acid-Binding Proteins | 1 | 2017 | 71 | 0.030 |
Why?
| | Recombinant Fusion Proteins | 1 | 2020 | 662 | 0.030 |
Why?
| | Seminiferous Tubules | 1 | 2016 | 13 | 0.030 |
Why?
| | Semen | 1 | 2016 | 20 | 0.030 |
Why?
| | Hypersensitivity, Delayed | 1 | 2016 | 29 | 0.030 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2018 | 557 | 0.030 |
Why?
| | Drug Resistance | 1 | 2017 | 145 | 0.030 |
Why?
| | Mice, Inbred NOD | 1 | 2018 | 597 | 0.030 |
Why?
| | Models, Economic | 1 | 2016 | 57 | 0.030 |
Why?
| | Cost Savings | 1 | 2016 | 84 | 0.030 |
Why?
| | Polymorphism, Genetic | 2 | 2010 | 635 | 0.030 |
Why?
| | Edema | 1 | 2016 | 130 | 0.030 |
Why?
| | Flowers | 1 | 2016 | 64 | 0.030 |
Why?
| | Research Personnel | 1 | 2017 | 186 | 0.030 |
Why?
| | Physician-Patient Relations | 1 | 2020 | 580 | 0.030 |
Why?
| | Antibodies, Bacterial | 1 | 2016 | 146 | 0.030 |
Why?
| | Adiponectin | 1 | 2017 | 243 | 0.030 |
Why?
| | Drug Monitoring | 1 | 2017 | 209 | 0.030 |
Why?
| | Equipment and Supplies | 1 | 2015 | 42 | 0.030 |
Why?
| | Kidney | 1 | 2023 | 1475 | 0.030 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2015 | 134 | 0.030 |
Why?
| | Body Burden | 1 | 2015 | 8 | 0.030 |
Why?
| | C-Peptide | 1 | 2015 | 162 | 0.030 |
Why?
| | Interleukin-2 | 1 | 2016 | 452 | 0.030 |
Why?
| | Salmonella typhimurium | 1 | 2016 | 183 | 0.030 |
Why?
| | Communication | 1 | 2020 | 924 | 0.030 |
Why?
| | Neoplasms | 1 | 2009 | 2712 | 0.030 |
Why?
| | Academic Medical Centers | 1 | 2017 | 506 | 0.030 |
Why?
| | Genotype | 2 | 2010 | 1876 | 0.030 |
Why?
| | Liver | 1 | 2022 | 1874 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2016 | 585 | 0.030 |
Why?
| | Activities of Daily Living | 1 | 2017 | 420 | 0.030 |
Why?
| | Prenatal Diagnosis | 1 | 2015 | 189 | 0.030 |
Why?
| | Data Display | 1 | 2013 | 20 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2020 | 964 | 0.020 |
Why?
| | E-Selectin | 1 | 2013 | 57 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 854 | 0.020 |
Why?
| | Chemokine CXCL10 | 1 | 2013 | 39 | 0.020 |
Why?
| | Testosterone | 1 | 2016 | 403 | 0.020 |
Why?
| | Health Services Accessibility | 1 | 2020 | 996 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2018 | 2166 | 0.020 |
Why?
| | Electronic Health Records | 1 | 2020 | 1088 | 0.020 |
Why?
| | Risk | 1 | 2015 | 906 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2013 | 298 | 0.020 |
Why?
| | Bone and Bones | 1 | 2015 | 318 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2016 | 786 | 0.020 |
Why?
| | Tetraethylammonium | 1 | 2011 | 16 | 0.020 |
Why?
| | beta Carotene | 1 | 2011 | 21 | 0.020 |
Why?
| | Vitamin A | 1 | 2011 | 59 | 0.020 |
Why?
| | Phenotype | 1 | 2019 | 3158 | 0.020 |
Why?
| | Receptors, Calcitriol | 1 | 2010 | 55 | 0.020 |
Why?
| | Calcium Chloride | 1 | 2010 | 11 | 0.020 |
Why?
| | Expert Testimony | 1 | 2010 | 40 | 0.020 |
Why?
| | Serotonin Antagonists | 1 | 2010 | 31 | 0.020 |
Why?
| | Benzimidazoles | 1 | 2011 | 175 | 0.020 |
Why?
| | B-Lymphocytes | 1 | 2015 | 849 | 0.020 |
Why?
| | Nitrites | 1 | 2010 | 86 | 0.020 |
Why?
| | Cholesterol | 1 | 2012 | 411 | 0.020 |
Why?
| | Intracellular Space | 1 | 2010 | 68 | 0.020 |
Why?
| | Extracellular Space | 1 | 2010 | 119 | 0.020 |
Why?
| | Potassium | 1 | 2010 | 145 | 0.020 |
Why?
| | Vasoconstrictor Agents | 1 | 2010 | 130 | 0.020 |
Why?
| | Nitric Oxide Synthase | 1 | 2010 | 242 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 979 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2017 | 2838 | 0.020 |
Why?
| | Serotonin | 1 | 2010 | 321 | 0.020 |
Why?
| | Angiotensins | 1 | 2007 | 8 | 0.020 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2007 | 23 | 0.020 |
Why?
| | Long-Term Care | 1 | 2007 | 106 | 0.020 |
Why?
| | Peptidyl-Dipeptidase A | 1 | 2007 | 52 | 0.020 |
Why?
| | Insurance, Health, Reimbursement | 1 | 2007 | 93 | 0.020 |
Why?
| | Fatty Acids | 1 | 2010 | 446 | 0.020 |
Why?
| | Models, Biological | 1 | 2013 | 1784 | 0.010 |
Why?
| | Peptides | 1 | 2011 | 980 | 0.010 |
Why?
| | Fructosamine | 1 | 2005 | 15 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2010 | 2029 | 0.010 |
Why?
| | Hemoglobins | 1 | 2007 | 353 | 0.010 |
Why?
| | Age Distribution | 1 | 2005 | 400 | 0.010 |
Why?
| | Sex Distribution | 1 | 2005 | 383 | 0.010 |
Why?
| | Hemoglobinuria | 1 | 2003 | 3 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 2 | 2003 | 2693 | 0.010 |
Why?
| | Sex Characteristics | 1 | 2003 | 770 | 0.010 |
Why?
| | Logistic Models | 1 | 2003 | 2081 | 0.010 |
Why?
| | Insulin Resistance | 1 | 2003 | 1231 | 0.010 |
Why?
|
|
Garg's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|